

Syntheses of serotonin, N-methylserotonin, bufotenine, and melatonin, and the first total synthesis of N-(Indol-3-yl)methyl-N-methyl-5-methoxytryptamine from tryptamine through a common intermediate, 1-hydroxytryptamine

著者	Somei Masanori, Yamada Fumio, Morikawa Harunobu
journal or publication title	Heterocycles
volume	46
page range	91-94
year	1997-01-01
URL	<a href="http://hdl.handle.net/2297/4346">http://hdl.handle.net/2297/4346</a>

SYNTHESES OF SEROTONIN, *N*-METHYLSEROTONIN, BUFOTENINE,  
AND MELATONIN, AND THE FIRST TOTAL SYNTHESIS OF *N*-(INDOL-3-  
YL)METHYL-*N*-METHYL-5-METHOXYTRYPTAMINE FROM TRYPTAMINE  
THROUGH A COMMON INTERMEDIATE, 1-HYDROXYTRYPTAMINE<sup>1</sup>

Masanori Somei,\* Fumio Yamada, and Harunobu Morikawa

Faculty of Pharmaceutical Sciences, Kanazawa University,


13-1 Takara-machi, Kanazawa 920, Japan

*Abstract* ————— Simple syntheses of serotonin (**1a**), *N*-methylserotonin (**1b**), bufotenine (**1c**), and melatonin (**2**), and the first total synthesis of *N*-(indol-3-yl)methyl-*N*-methyl-5-methoxytryptamine (**3**) from tryptamine (**4a**) are reported through acid catalyzed nucleophilic substitution reaction of 1-hydroxytryptamines.

Tryptamine alkaloids such as serotonin (**1a**, Scheme 1),<sup>2</sup> *N*-methylserotonin (**1b**),<sup>3</sup> bufotenine (**1c**),<sup>4a,b</sup> and melatonin (**2**)<sup>5</sup> are biologically important amines in animals and plants. As a member of the alkaloid family, *N*-(indol-3-yl)methyl-*N*-methyl-5-methoxytryptamine (**3**)<sup>6</sup> was recently isolated from the roots of *Antirhea lucida* (Sw.) Hook (Rubiaceae). Our 1-hydroxyindole hypotheses<sup>7</sup> expect that 1-hydroxytryptamine is a common biosynthetic intermediate for these alkaloids. Attempts to verify the hypotheses have led us to disclose acid catalyzed transformations of 1-hydroxytryptamines (**6**, **9**, **12**, and **17**) into **1a**, **2**, and **3**.

The synthesis of **2** has already been achieved in 80% yield<sup>7c,f</sup> from *N*-acetyl-1-hydroxytryptamine (**6a**) utilizing acid catalyzed regioselective nucleophilic substitution at the 5-position.<sup>7</sup> Based on the result, simple syntheses of **1a** and **1b** from **4a** were established as follows. *N*-Methoxycarbonyltryptamine (**4b**), available from **4a** by a conventional method, was converted to **5** (83%) by the reduction with triethylsilane<sup>8</sup> in CF<sub>3</sub>COOH (Et<sub>3</sub>SiH-TFA). Oxidation of **5** with Na<sub>2</sub>WO<sub>4</sub>·2H<sub>2</sub>O and 30% H<sub>2</sub>O<sub>2</sub><sup>7,9</sup> (Na<sub>2</sub>WO<sub>4</sub>-H<sub>2</sub>O<sub>2</sub>) produced *N*-methoxycarbonyl-1-hydroxytryptamine (**6b**, 67%). The reaction of **6b** with 85% HCOOH at room temperature for 20 min afforded **7a** (15%) and **7b** (50%). Interconversion between **7a** and **7b** was readily attained. Thus, treatment of **7b** with 85% HCOOH at room temperature for

## Scheme 1



48 h afforded **7a** (69%), while its alkaline hydrolysis with 2N-NaOH in MeOH gave **7b** (76%). Further treatment of **7b** with LiAlH<sub>4</sub> in refluxing Et<sub>2</sub>O-THF afforded **1b** (65%). Hydrolysis of **7b** to **1a** proceeded in 73% yield by the treatment with 10% NaOH in refluxing MeOH.

An attempt to convert *N,N*-dimethyl-1-hydroxytryptamine (**9**), prepared from **4c** through **8** as reported previously,<sup>7f</sup> directly into bufotenine (**1c**) by the reaction with 85% HCOOH was unsuccessful. However, the treatment of **9** with more acidic 5% H<sub>2</sub>SO<sub>4</sub>-H<sub>2</sub>O at reflux for 6 h produced **1c**<sup>4c</sup> in 47% yield together with **4c** (16%). When the solvent was changed to MeOH under similar reaction conditions, **9** afforded **10a** (57%), **1c** (7%), and **4c** (11%). The structure of **10a** was confirmed by comparing its <sup>1</sup>H-NMR spectrum with that of 1-acetyl derivative (**10b**), where the 1-acetyl group deshielded the C-7 proton (d, *J* = 9.0 Hz) by about 1 ppm. The cleavage of the methoxy group of **10a** using BBr<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub>-toluene also gave **1c**<sup>4c</sup> (63%).

Total synthesis of **3**<sup>6</sup> was carried out by the following two routes. The conventional LiAlH<sub>4</sub> reduction of **4b** to **4d**, followed by the treatment with ClCOOMe-Et<sub>3</sub>N, afforded **4e** (94% overall yield). Further reduction of **4e** with Et<sub>3</sub>SiH-TFA afforded **11** (95%). Subsequent oxidation of **11** with Na<sub>2</sub>WO<sub>4</sub>-H<sub>2</sub>O<sub>2</sub> gave *N*-methoxycarbonyl-*N*-methyl-1-hydroxytryptamine (**12**, 77%). Treatment of **12** with 5% H<sub>2</sub>SO<sub>4</sub> in refluxing MeOH produced **13a** (39%). Hydrolysis of **13a** with 40% NaOH in refluxing MeOH afforded **13b**<sup>10</sup> (93%). Then our Bu<sub>3</sub>P<sup>11</sup> catalyzed reaction of gramine (**14**) with nucleophiles was successfully applied to **13b** in refluxing MeCN culminating in the first total synthesis of **3**<sup>12</sup> in 78% yield. On the other hand, similar reaction of **14** with **4d** produced **15** (67%) together with unreacted **4d** (32%). It is interesting to note that selective reduction of tryptamine part of **15** was realized with NaBH<sub>3</sub>CN<sup>13</sup> in AcOH-TFA (3:1, v/v) resulting in the formation of **16** (71%). Subsequent oxidation of **16** with Na<sub>2</sub>WO<sub>4</sub>-H<sub>2</sub>O<sub>2</sub> gave **17** (51%). Treatment of **17** with BF<sub>3</sub>·MeOH in MeOH at 65°C for 3 h accomplished an alternative route to **3** (15%)<sup>14</sup> together with **15** (9%) and unreacted **17** (21%).

In conclusion, we disclosed that under acidic conditions 1-hydroxytryptamines readily transform to biologically important tryptamine alkaloids (**1a-c**, **2**, and **3**). From the synthetic point of view, the reaction has a probability to produce various 5-substituted tryptamines simply by choosing suitable nucleophiles. Investigations along this line are now in progress.

## REFERENCES AND NOTES

1. Dedicated to the memory of the late Dr. Shun-ichi Yamada. This is Part 81 of a series entitled "The Chemistry of Indoles". Part 80: M. Somei, Y. Yamada, K. Kitagawa, K. Sugaya, Y. Tomita, F.

- Yamada, and K. Nakagawa, *Heterocycles*, 1997, **45**, 435.
2. M. M. Rapport, A. A. Green, and I. H. Page, *Science*, 1948, **108**, 329; *idem*, *J. Biol. Chem.*, 1948, **176**, 1243; M. M. Rapport, *ibid.*, 1949, **180**, 961.
  3. A. Stoll, F. Troxler, J. Peyer, and A. Hofmann, *Helv. Chim. Acta*, 1955, **38**, 1452.
  4. a) T. Wieland and W. Motzel, *Ann.*, 1953, **581**, 10; b) V. L. Stromberg, *J. Am. Chem. Soc.*, 1954, **76**, 1707; c) It should be mentioned that even the purest synthetic bufotenine (**1c**) will not crystallize in our hands. The melting points of methiodide and picrate of **1c** are in good agreement with the reported ones.<sup>4a,b</sup>
  5. A. B. Lerner, J. D. Case, Y. Takahashi, T. H. Lee, and W. Mori, *J. Am. Chem. Soc.*, 1958, **80**, 2587.
  6. B. Weniger, W. Rafik, J. Bastida, J. -C. Quirion, and R. Anton, *Planta Med.*, 1995, **61**, 569.
  7. a) M. Somei, T. Kawasaki, Y. Fukui, F. Yamada, T. Kobayashi, H. Aoyama, and D. Shinmyo, *Heterocycles*, 1992, **34**, 1877; b) F. Yamada, Y. Fukui, D. Shinmyo, and M. Somei, *ibid.*, 1993, **36**, 99; c) M. Somei and Y. Fukui, *ibid.*, 1993, **36**, 1859; d) F. Yamada, D. Shinmyo, and M. Somei, *ibid.*, 1994, **38**, 273; e) M. Somei, K. Kobayashi, K. Tanii, T. Mochizuki, Y. Kawada, and Y. Fukui, *ibid.*, 1995, **40**, 119; f) M. Somei, K. Yamada, M. Hasegawa, M. Tabata, Y. Nagahama, H. Morikawa, and F. Yamada, *ibid.*, 1996, **43**, 1855; g) M. Hasegawa, M. Tabata, K. Satoh, F. Yamada, and M. Somei, *ibid.*, 1996, **43**, 2333.
  8. A. E. Lanzilotti, R. Littell, W. J. Fanshawe, T. C. McKenzie, and F. M. Lovell, *J. Org. Chem.*, 1979, **44**, 4809.
  9. M. Somei and T. Kawasaki, *Heterocycles*, 1989, **29**, 1251; Review: M. Somei, *J. Synth. Org. Chem.*, 1991, **49**, 205; M. Somei, T. Kawasaki, K. Shimizu, Y. Fukui, and T. Ohta, *Chem. Pharm. Bull.*, 1991, **39**, 1905; M. Somei, K. Kobayashi, K. Shimizu, and T. Kawasaki, *Heterocycles*, 1992, **33**, 77.
  10. T. Marczyński, *Dissertationes Pharm.*, 1959, **11**, 296; S. Wilkinson, *J. Chem. Soc.*, 1958, 2079.
  11. M. Somei, Y. Karasawa, and C. Kaneko, *Heterocycles*, 1981, **16**, 941.
  12. Colorless oil. Although IR and <sup>1</sup>H-NMR data differ slightly from the reported ones,<sup>6</sup> we found that proton signals shift markedly depending on the deuterated solvent. The data of <sup>13</sup>C-NMR are completely identical with the reported ones.<sup>6</sup> <sup>1</sup>H-NMR (5% CD<sub>3</sub>OD in CDCl<sub>3</sub>) δ: 2.40 (3H, s), 2.81 (2H, t, *J*=8.1 Hz), 3.00 (2H, t, *J*=8.1 Hz), 3.79 (3H, s), 3.85 (2H, s), 6.82 (1H, dd, *J*=8.8 and 2.5 Hz), 6.95 (1H, s), 6.97 (1H, d, *J*=2.5 Hz), 7.11 (1H, ddd, *J*=8.1, 7.0, and 1.0 Hz), 7.17 (1H, s), 7.18 (1H, ddd, *J*=8.1, 7.0, and 1.0 Hz), 7.23 (1H, d, *J*=8.8 Hz), 7.37 (1H, dt, *J*=8.1 and 1.0 Hz), 7.69 (1H, dt, *J*=8.1 and 1.0 Hz). <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ: 23.5, 42.3, 52.7, 55.9, 57.6, 100.7, 111.0, 111.8, 112.0, 113.1, 114.3, 119.4, 119.5, 121.9, 122.4, 123.6, 127.9, 131.4, 136.2 (2C), 153.8. IR (CHCl<sub>3</sub>): 3450, 2780, 1621, 1585, 1483, 1451 cm<sup>-1</sup>. High Resolution MS *m/z*: Calcd for C<sub>21</sub>H<sub>23</sub>N<sub>3</sub>O: 333.1841. Found: 333.1852.
  13. G. W. Gribble and J. H. Hoffman, *Synthesis*, 1977, 859; M. E. Flaugh, D. L. Mullen, R. W. Fuller, and N. R. Mason, *J. Med. Chem.*, 1988, **31**, 1746.
  14. Optimum reaction conditions have not been made yet.

Received, 27th February, 1997